France· FR:64743778
CARVYKTI 3,2 x 1 000 000 - 1 x 100 000 000 cellules, dispersion pour perfusion
A ciltacabtagene autoleucel product containing ciltacabtagène autoleucel, registered in France by JANSSEN CILAG INTERNATIONAL NV. The same ATC class is registered in 13 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Ciltacabtagene autoleucel is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XL05 (ciltacabtagene autoleucel), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Ciltacabtagene autoleucel · ATC L01XL05
13 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CILTACABTAGÈNE AUTOLEUCEL
- Manufacturer
- JANSSEN CILAG INTERNATIONAL NV
- Country
- France (FR)
- ATC code
- L01XL05
- ATC class
- Ciltacabtagene autoleucel
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550891171 poche EVA : éthylène vinyl acétate copolymère avec tube d'addition scellé et deux ports de piquage disponibles contenant soit 30mL (poche de 50mL) ou 70mL (poche de 250 mL)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ciltacabtagene autoleucel in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesCARVYKTIJanssen Biotech, Inc.
- SwitzerlandCarvyktiJanssen-Cilag AG
- CzechiaCARVYKTIJanssen-Cilag International N.V., Beerse
- SpainCARVYKTI 3,2 × 10e6 - 1 × 10e8 CELULAS DISPERSION PARA PERFUSIONJanssen-Cilag International N.V
- FinlandCARVYKTIJanssen-Cilag International NV
- United KingdomCarvykti 3.2million-100million cells dispersion for infusion bagsJanssen-Cilag Ltd
- BelgiumCarvykti 3,2 x 10*6-1,0 x 10*8 cellsJanssen-Cilag International
- IcelandCarvyktiJanssen-Cilag International NV*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Carvykti
- Liechtenstein · Carvykti
- Norway · Carvykti
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ebc5c908-d51c-4049-be1c-8f82f0b0ddd8 GET /v1/drugs/ebc5c908-d51c-4049-be1c-8f82f0b0ddd8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64743778",
"date_amm": "2022-05-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/22/1648",
"substance": "CILTACABTAGÈNE AUTOLEUCEL",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "dispersion pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Oui"
}See everything about ciltacabtagene autoleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.